- $35.82m
- $33.92m
- $24.05m
Precipio Q1 revenue rises on higher pathology sales
Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%
Brief: Precipio Identifies Unauthorized Access To Isolated Storage No Operational Impact
Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers
Brief: Precipio Inc - Terminates Sales Agreement With A.G.P. - SEC Filing
Brief: Precipio Terminates Its At-The-Market Instrument
Brief: Precipio Announces Its Q1-2025 Financial Results
Brief: Precipio Announces Employee Stock Option Plan Repricing
Brief: Precipio Provides Status Update On Current Business Matters
Brief: Precipio Secures Short-Term $500K Credit Facility
Brief: Precipio Shareholders To Expect More Quarter-To-Quarter Volatility In Pathology Division Revenue
Brief: Precipio Inc Company Has Regained Compliance With Nasdaq Bid Price Rule - SEC Filing
Brief: Precipio’s Q3 Cash Burn From Operations (Unaudited) Declines 59% YoY, From $2.5M In Q3-2022 To Approximately $1M In Q3-2023
Brief: Precipio Inc Reduces Revenue Required From Products Division To Reach Breakeven $6M Annually
Brief: Precipio Inc Says Implemented A 1-For-20 Reverse Stock Split Of Outstanding Shares Of Company's Common Stock
Precipio Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Precipio Inc Projected To Report Cash Burn Of $3.1 Mln For 6 Months Ended June 30
Brief: Precipio, Inc. posts Q2 product revenue USD 3.5 million
U.S. RESEARCH ROUNDUP-Catalent, Estee Lauder Companies, Marqeta